GlycoMimetics Past Earnings Performance
Past criteria checks 0/6
GlycoMimetics has been growing earnings at an average annual rate of 8.2%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been declining at an average rate of 63.1% per year.
Key information
8.2%
Earnings growth rate
16.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -63.1% |
| Return on equity | -349.3% |
| Net Margin | -397,350.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
We're A Little Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Rate
Jun 27
GlycoMimetics Can Become A Game Changer In Blood Cancers
Mar 21Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?
Mar 20GlycoMimetics: Drug Approval Is Not Coming In 2024, But The Hype Could Be Real
Jan 30Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?
Nov 19Will GlycoMimetics (NASDAQ:GLYC) Spend Its Cash Wisely?
Jan 30Here's Why GlycoMimetics (NASDAQ:GLYC) Must Use Its Cash Wisely
Oct 06GlycoMimetics has a new Chief Medical Officer
Sep 06GlycoMimetics GAAP EPS of $0.25 beats by $0.53, revenue of $75K
Aug 03GlycoMimetics (NASDAQ:GLYC) Will Have To Spend Its Cash Wisely
Jun 04GlycoMimetics Positive Data For AML Therapy Increasingly Likely
Mar 16Here's Why We're Watching GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation
Nov 20We Think GlycoMimetics (NASDAQ:GLYC) Needs To Drive Business Growth Carefully
Aug 20GlycoMimetics says first patient dosed in investigator-sponsored mid-stage uproleselan study
May 26Here's Why It's Unlikely That GlycoMimetics, Inc.'s (NASDAQ:GLYC) CEO Will See A Pay Rise This Year
May 12GlycoMimetics EPS beats by $0.04
May 03Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation
Mar 26GlycoMimetics' (NASDAQ:GLYC) Shareholders Are Down 83% On Their Shares
Feb 19GlycoMimetics, Inc. (NASDAQ:GLYC) Insiders Increased Their Holdings
Jan 24How Much Did GlycoMimetics' (NASDAQ:GLYC) CEO Pocket Last Year?
Dec 28New data from GlycoMimetics highlights the efficacy Rivipansel in vaso-occlusive crisis in sickle cell disease
Dec 07Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation
Dec 07The Investment Case For GlycoMimetics
Nov 17Revenue & Expenses Breakdown
How GlycoMimetics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -40 | 17 | 19 |
| 30 Jun 24 | 0 | -39 | 18 | 23 |
| 31 Mar 24 | 0 | -37 | 19 | 21 |
| 31 Dec 23 | 0 | -37 | 19 | 20 |
| 30 Sep 23 | 0 | -38 | 20 | 21 |
| 30 Jun 23 | 0 | -37 | 19 | 20 |
| 31 Mar 23 | 0 | -42 | 20 | 24 |
| 31 Dec 22 | 0 | -47 | 19 | 28 |
| 30 Sep 22 | 0 | -54 | 19 | 35 |
| 30 Jun 22 | 0 | -63 | 19 | 44 |
| 31 Mar 22 | 0 | -64 | 18 | 46 |
| 31 Dec 21 | 1 | -63 | 17 | 47 |
| 30 Sep 21 | 1 | -62 | 17 | 46 |
| 30 Jun 21 | 2 | -58 | 16 | 44 |
| 31 Mar 21 | 2 | -58 | 16 | 43 |
| 31 Dec 20 | 10 | -51 | 17 | 45 |
| 30 Sep 20 | 10 | -50 | 17 | 45 |
| 30 Jun 20 | 9 | -50 | 16 | 45 |
| 31 Mar 20 | 9 | -51 | 15 | 48 |
| 31 Dec 19 | 0 | -58 | 14 | 47 |
| 30 Sep 19 | 0 | -57 | 13 | 48 |
| 30 Jun 19 | 0 | -55 | 13 | 47 |
| 31 Mar 19 | 0 | -51 | 12 | 43 |
| 31 Dec 18 | 0 | -48 | 11 | 40 |
| 30 Sep 18 | 0 | -44 | 11 | 35 |
| 30 Jun 18 | 0 | -40 | 11 | 31 |
| 31 Mar 18 | 0 | -37 | 11 | 27 |
| 31 Dec 17 | 0 | -33 | 10 | 24 |
| 30 Sep 17 | 0 | -32 | 9 | 23 |
| 30 Jun 17 | 0 | -32 | 9 | 24 |
| 31 Mar 17 | 0 | -32 | 9 | 24 |
| 31 Dec 16 | 0 | -32 | 9 | 23 |
| 30 Sep 16 | 0 | -32 | 8 | 24 |
| 30 Jun 16 | 0 | -32 | 8 | 23 |
| 31 Mar 16 | 20 | -13 | 8 | 25 |
| 31 Dec 15 | 20 | -13 | 8 | 25 |
| 30 Sep 15 | 20 | -11 | 8 | 23 |
| 30 Jun 15 | 20 | -11 | 7 | 23 |
| 31 Mar 15 | 15 | -13 | 7 | 21 |
| 31 Dec 14 | 15 | -11 | 7 | 20 |
| 30 Sep 14 | 15 | -8 | 5 | 17 |
| 30 Jun 14 | 15 | -5 | 4 | 15 |
| 31 Mar 14 | 0 | -16 | 4 | 13 |
| 31 Dec 13 | 4 | -11 | 3 | 12 |
Quality Earnings: GLYC is currently unprofitable.
Growing Profit Margin: GLYC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GLYC is unprofitable, but has reduced losses over the past 5 years at a rate of 8.2% per year.
Accelerating Growth: Unable to compare GLYC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GLYC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: GLYC has a negative Return on Equity (-349.28%), as it is currently unprofitable.